JP2015528446A - 腎毒性を低減してがんを処置するための改良法 - Google Patents

腎毒性を低減してがんを処置するための改良法 Download PDF

Info

Publication number
JP2015528446A
JP2015528446A JP2015527429A JP2015527429A JP2015528446A JP 2015528446 A JP2015528446 A JP 2015528446A JP 2015527429 A JP2015527429 A JP 2015527429A JP 2015527429 A JP2015527429 A JP 2015527429A JP 2015528446 A JP2015528446 A JP 2015528446A
Authority
JP
Japan
Prior art keywords
cancer
tumor
lipoplatin
patient
cisplatin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015527429A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015528446A5 (enExample
Inventor
ブリカス、テニ
スタソポウロス、ジョージ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2015528446A publication Critical patent/JP2015528446A/ja
Publication of JP2015528446A5 publication Critical patent/JP2015528446A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2015527429A 2012-08-13 2012-08-13 腎毒性を低減してがんを処置するための改良法 Pending JP2015528446A (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2012/050630 WO2014027996A1 (en) 2012-08-13 2012-08-13 Improved methods for treating cancer with reduced renal toxicity

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017104084A Division JP2017178960A (ja) 2017-05-26 2017-05-26 腎毒性を低減してがんを処置するための改良法

Publications (2)

Publication Number Publication Date
JP2015528446A true JP2015528446A (ja) 2015-09-28
JP2015528446A5 JP2015528446A5 (enExample) 2015-11-05

Family

ID=50101360

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015527429A Pending JP2015528446A (ja) 2012-08-13 2012-08-13 腎毒性を低減してがんを処置するための改良法

Country Status (13)

Country Link
US (1) US20150258140A1 (enExample)
EP (1) EP2882420A4 (enExample)
JP (1) JP2015528446A (enExample)
CN (1) CN104736143A (enExample)
AU (1) AU2012387681A1 (enExample)
BR (1) BR112015003111A2 (enExample)
CA (1) CA2882156A1 (enExample)
EA (1) EA201590325A1 (enExample)
IN (1) IN2015KN00375A (enExample)
MA (1) MA37931A1 (enExample)
SG (1) SG11201501146VA (enExample)
WO (1) WO2014027996A1 (enExample)
ZA (1) ZA201501123B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015520152A (ja) * 2012-05-11 2015-07-16 リセット セラピューティークス， インコーポレイテッド クリプトクロム調節薬としてのカルバゾール含有スルホンアミド

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006523713A (ja) * 2003-04-16 2006-10-19 セレーター ファーマスーティカルズ、インク． 薬剤併用物送達用組成物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04169532A (ja) * 1990-11-01 1992-06-17 Sumitomo Pharmaceut Co Ltd 脂溶性白金錯体含有リポソーム製剤
JPH04169531A (ja) * 1990-11-01 1992-06-17 Sumitomo Pharmaceut Co Ltd 脂溶性白金錯体を含有するリポソーム製剤
EP0551169A1 (en) * 1992-01-10 1993-07-14 Takeda Chemical Industries, Ltd. Liposome composition and production thereof
EP0929293B1 (en) * 1996-08-23 2003-10-22 Sequus Pharmaceuticals, Inc. Liposomes containing a cisplatin compound
DE19954613A1 (de) * 1999-11-12 2001-05-17 Enthone Omi Deutschland Gmbh Verfahren zur stromlosen Verzinnung von Kupfer oder Kupferlegierungen
GR20060100144A (el) * 2006-03-03 2007-10-17 Θεραπεια του καρκινου με χρηση οξαλιπλατινης εγκλεισμενης μεσα σε λιποσωματα και απο κοινου εγκλεισμος στο λιποσωμιακο μοριο περισσοτερων απο ενος φαρμακευτικου παρασκευασματος h gene
EP2123258A1 (en) * 2008-05-23 2009-11-25 Liplasome Pharma A/S Liposomes for drug delivery
US20120197060A1 (en) * 2009-06-18 2012-08-02 University Of Utah Research Foundation Radiation enhanced macromolecular delivery of therapeutic agents for chemotherapy technology

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006523713A (ja) * 2003-04-16 2006-10-19 セレーター ファーマスーティカルズ、インク． 薬剤併用物送達用組成物

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BOULIKAS，T.，ET AL.: ""Liposomally encapsulated cisplatin and oxaliplatin as revolutionary chemotherapy drugs"", ANTICANCER RESEARCH, vol. 24, JPN5009004713, 2004, pages 4265 - 4266, ISSN: 0003319433 *
JOURNAL OF CLINICAL ONCOLOGY, vol. Vol.29, No.15, Supp.1, JPN6016018366, 2011, pages 7072, ISSN: 0003319432 *
JOURNAL OF DRUG DELIVERY & THERAPEUTICS, vol. 2, no. 3, JPN6016018365, 2012, pages 106 - 109, ISSN: 0003319431 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015520152A (ja) * 2012-05-11 2015-07-16 リセット セラピューティークス， インコーポレイテッド クリプトクロム調節薬としてのカルバゾール含有スルホンアミド

Also Published As

Publication number Publication date
BR112015003111A2 (pt) 2017-10-10
SG11201501146VA (en) 2015-05-28
CN104736143A (zh) 2015-06-24
WO2014027996A1 (en) 2014-02-20
MA37931A1 (fr) 2016-07-29
EP2882420A1 (en) 2015-06-17
EP2882420A4 (en) 2016-06-01
ZA201501123B (en) 2020-02-26
US20150258140A1 (en) 2015-09-17
CA2882156A1 (en) 2014-02-20
IN2015KN00375A (enExample) 2015-07-10
EA201590325A1 (ru) 2015-09-30
AU2012387681A1 (en) 2015-03-05

Similar Documents

Publication Publication Date Title
JP6963146B1 (ja) 癌を治療するためのｋｒａｓ阻害剤の投与
RU2695228C2 (ru) Прерывистое введение ингибитора mdm2
CN105611939A (zh) 用于治疗成胶质细胞瘤的组合疗法
AU2018242612B2 (en) Dose and regimen for an HDM2-p53 interaction inhibitor in hematological tumors
JP2021509395A (ja) がんの治療に使用するためのミルシクリブの製剤及びその治療的組み合わせ
KR20240074779A (ko) 약학적 조성물 및 이의 용도
WO2023230567A1 (en) Gcn2 modulator for treating cancer
Liu et al. Preclinical and early clinical studies of a novel compound SYHA1813 that efficiently crosses the blood–brain barrier and exhibits potent activity against glioblastoma
BR112021011493A2 (pt) Terapia de combinação para tratamento de câncer
JP2015528446A (ja) 腎毒性を低減してがんを処置するための改良法
WO2012149308A1 (en) Method of treating lymphoma using pyridopyrimidinone inhibitors of pi3k/mtor
JP2017178960A (ja) 腎毒性を低減してがんを処置するための改良法
JP2025531278A (ja) 医薬組成物およびその使用
DK2992874T3 (en) LIPOSOM FOR TOPIC SUBMISSION AND USE THEREOF
JP2015524467A (ja) Ｌｉｐｏｐｌａｔｉｎを使用するがんの処置方法
KR20150088237A (ko) 신장 독성이 감소된 개선된 암 치료방법
TWI902129B (zh) 給予kras抑制劑治療癌症
HK1211218A1 (en) Combinations of a pi3k/akt inhibitor compound with an her3/egfr inhibitor compound and use thereof in the treatment of a hyperproliferative disorder
CN118846073A (zh) 一种酪氨酸激酶抑制剂的新应用
HK40066210A (zh) 给药kras抑制剂治疗癌症
HK40066210B (zh) 给药kras抑制剂治疗癌症
EA047200B1 (ru) Введение доз ингибитора kras для лечения форм рака

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150710

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20150710

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20150710

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150811

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150811

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160518

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20160520

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160812

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170126